FRANKLIN LAKES, N.J., July 23, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on manag

SECAUCUS, N.J., July 23, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2019.

NEW YORK, July 23, 2019 /PRNewswire/ -- From 2014 to 2018, private insurance claim lines1 for non-hospital-based provider-to-patient telehealth grew 1,393 percent, according to a new

IRVING, Texas, July 23, 2019 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the University of Puerto Rico (UPR) has become the 28th member of its 

PASADENA, Calif., July 23, 2019 /PRNewswire/ -- New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholest

BEIJING, July 23, 2019 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solutions provider and an operator of the network of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord Medical Cancer Center (a

SAN JOSE, Calif., July 23, 2019 /PRNewswire/ -- Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the enrollment and randomization of the first patient in the TARGET BP I global clinical trial. Piedmont Heart Institute in Atlanta is the first hospital center worldwide to enroll

BERKELEY, Calif., July 23, 2019 /PRNewswire/ -- Today, the U.S. Patent and Trademark Office has awarded two new patents to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering methods of the CRISPR-Cas9 gene-editing technology.

ST. LOUIS, July 23, 2019 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its financial results for the second quarter ended June 30, 2019, reporting diluted earnings per share (EPS) of $1.18, and Adjusted Diluted EPS of $1.34.In summary, the 2019 second quarter results were as follows

TEL AVIV, Israel, July 23, 2019 /PRNewswire/ -- Stero Biotechs, an Israel-based, clinical-stage company focused on Cannabidiol (CBD) formulation research and development, received its second Helsinki approval to move forward with a second Phase 2a clinical trial. The trial will be a randomized, double-blin